Novonesis Group sees a 1.5% share dip as Danish probiotic & ingredient market pressures hit; valuation stays peer‑aligned, but growth relies on scaling, compliance & reimbursement success.
How DNB Carnegie’s downgrade to hold, with a higher target price, impacted Novonesis’ 1.5% C25‑driven market rise—and why investors, clinicians, and payers should watch upcoming clinical data.